Venus Remedies
VENUSREM NSE
Venus Remedies
HealthcareNSE: VENUSREM BSE: 526953 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹2,139 Cr
Volatility
Moderate
P/E Ratio
18.6
EBITDA
₹147 Cr
Return on Equity
8.08%
Debt to Equity
0.02
Book Value
₹496.56
52W High
₹2,044.3
52W Low
₹424
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Company has delivered good profit growth of 21.8% CAGR over last 5 years
Weaknesses
3- Stock is trading at 3.26 times its book value
- The company has delivered a poor sales growth of 7.18% over past five years.
- Company has a low return on equity of 10.5% over last 3 years.
Growth Rate
Revenue Growth
15.07% higher than
3Y
Net Income Growth
124% higher than
3Y
Cash Flow Change
132% lower than
3Y
ROE
38.36% higher than
3Y
ROCE
51.9% lower than
3Y
EBITDA Margin (Avg.)
49.09% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 168 | 143 | 195 | 109 | 170 | 177 | 195 | 137 | 193 | 180 | 259 | 179 |
| Expenses | 85 | 150 | 131 | 176 | 97 | 163 | 158 | 166 | 122 | 162 | 143 | 196 | 145 |
| Operating Profit | 10 | 18 | 12 | 19 | 11 | 8 | 18 | 29 | 15 | 31 | 38 | 63 | 34 |
| OPM % | 11% | 11% | 8% | 10% | 10% | 4.5% | 10% | 15% | 11% | 16% | 21% | 24% | 19% |
| Other Income | 2 | 3 | 2 | 4 | 2 | 8 | 12 | 7 | 3 | 2 | 3 | 5 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 8 | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 |
| PBT | 5 | 14 | 8 | 17 | 7 | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 |
| Tax % | 77% | 31% | 12% | 40% | 82% | 61% | 21% | 32% | 24% | 24% | 24% | 23% | 24% |
| Net Profit | 1 | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 | 48 | 23 |
| EPS in Rs | 0.88 | 7.44 | 5.12 | 7.86 | 0.91 | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.54 | 17.18 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 455 | 407 | 400 | 372 | 322 | 335 | 544 | 597 | 552 | 596 | 640 | 770 | 811 |
| Expenses | 366 | 326 | 349 | 333 | 289 | 295 | 490 | 535 | 492 | 537 | 577 | 622 | 645 |
| Operating Profit | 89 | 81 | 51 | 39 | 33 | 41 | 54 | 62 | 60 | 60 | 64 | 147 | 166 |
| OPM % | 20% | 20% | 13% | 11% | 10% | 12% | 10% | 10% | 11% | 10% | 10% | 19% | 20% |
| Other Income | 1 | 2 | 2 | 2 | -3 | -4 | 43 | 8 | 10 | 12 | 31 | 13 | 12 |
| Interest | 41 | 38 | 34 | 35 | 25 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 46 | 42 | 40 | 34 | 34 | 32 | 35 | 34 | 32 | 26 | 23 | 26 | 26 |
| PBT | 3 | 4 | -22 | -28 | -30 | -8 | 49 | 36 | 38 | 45 | 72 | 134 | 152 |
| Tax % | -95% | 52% | -21% | 11% | -4% | 24% | -27% | -12% | 30% | 36% | 37% | 23% | — |
| Net Profit | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 45 | 103 | 116 |
| EPS in Rs | 4.51 | 1.49 | -13.84 | -24.87 | -23.15 | -8.1 | 50.05 | 30.46 | 19.88 | 21.31 | 33.9 | 76.9 | 86.92 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 445 | 426 | 376 | 350 | 320 | 311 | 388 | 427 | 447 | 474 | 548 | 650 |
| Borrowings | 321 | 335 | 312 | 307 | 298 | 220 | 51 | 43 | 42 | 41 | 2 | 12 |
| Other Liabilities | 64 | 70 | 65 | 82 | 102 | 100 | 104 | 97 | 98 | 98 | 153 | 178 |
| Total Liabilities | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 |
| Fixed Assets | 444 | 452 | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 229 | 232 |
| CWIP | 78 | 80 | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 21 | 26 | 51 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 19 | 84 | 238 |
| Other Assets | 319 | 310 | 293 | 297 | 304 | 330 | 269 | 314 | 339 | 368 | 376 | 333 |
| Total Assets | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 68 | 47 | 59 | 31 | 45 | 78 | 132 | 41 | 37 | 37 | 86 | 156 |
| Investing | -67 | 3 | -18 | 8 | -11 | -5 | 57 | -17 | -58 | -8 | -77 | -182 |
| Financing | -1 | -46 | -44 | -39 | -35 | -73 | -162 | -9 | -1 | -1 | -1 | -3 |
| Net Cash Flow | -1 | 3 | -4 | 0 | -1 | 0 | 27 | 14 | -22 | 28 | 9 | -29 |
| Free Cash Flow | 59 | 46 | 41 | 19 | 35 | 70 | 132 | 41 | 29 | 24 | 69 | 118 |
| CFO/OP | 76 | 58 | 116 | 79 | 139 | 190 | 245 | 66 | 61 | 89 | 160 | 129 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 55 | 43 | 46 | 43 | 33 | 21 | 24 | 51 | 49 | 64 | 49 |
| Inventory Days | 194 | 219 | 226 | 246 | 286 | 296 | 129 | 118 | 132 | 125 | 97 | 122 |
| Days Payable | 40 | 38 | 48 | 52 | 72 | 77 | 76 | 47 | 56 | 55 | 89 | 107 |
| Cash Conversion Cycle | 204 | 236 | 221 | 240 | 257 | 252 | 74 | 95 | 127 | 120 | 72 | 64 |
| Working Capital Days | 54 | 69 | 54 | 25 | -1 | 73 | 71 | 82 | 109 | 118 | 86 | 97 |
| ROCE % | 6% | 5% | 2% | 1% | 1% | 2% | 8% | 8% | 8% | 9% | 11% | 22% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Venus Remedies insights
30 extracted metrics + investor summaries across FY15–FY26.
Documents
1
Compliances-Reg.24(A)-Annual Secretarial Compliance
6 May - Submitted annual secretarial compliance report for FY ended 31 March 2026; no non-compliances reported. 6 May - Submitted annual secretarial compliance report for FY ended 31 March 2026; no non-compliances reported.
2
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 May - Newspaper publication of Notice to shareholders about transfer of physical shares as per SEBI circular. 5 May - Newspaper publication of Notice to shareholders about transfer of physical shares as per SEBI circular.
3
Disclosure Of Social Media Post On Transfer Of Physical Shares.
4 May - Company shared social media links for special window to re-lodge transfer requests of physical shares. 4 May - Company shared social media links for special window to re-lodge transfer requests of physical shares.
4
Disclosure Of Social Media Post On Transfer Of Physical Shares.
4 May - Company shared social media links for special window to re-lodge transfer requests of physical shares. 4 May - Company shared social media links for special window to re-lodge transfer requests of physical shares.
5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Regulation 74(5) compliance certificate submitted for quarter ended 31 March 2026. 8 Apr - Regulation 74(5) compliance certificate submitted for quarter ended 31 March 2026.
5
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association 21 Aug 2026
General_Announcements
Frequently Asked Questions about Venus Remedies
What does Venus Remedies Ltd do?
Incorporated in 1989, Venus Remedies
Ltd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies. It operates across 100+ countries, with a product basket of 195+, 1,100+ marketing authorisation...
Where is Venus Remedies Ltd (VENUSREM) listed?
Venus Remedies Ltd trades as VENUSREM on the NSE and under code 526953 on the BSE.
Which sector does Venus Remedies Ltd belong to?
Venus Remedies Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Venus Remedies Ltd?
Venus Remedies Ltd has a market capitalisation of ₹2,139 Cr, which places it in the Small Cap band.
What is the PE ratio of Venus Remedies Ltd?
Venus Remedies Ltd trades at a PE ratio of 18.60, against a book value of ₹496.56 per share.
What is the 52-week high and low of Venus Remedies Ltd?
Over the last 52 weeks Venus Remedies Ltd has traded between ₹424 and ₹2,044.3.
Does Venus Remedies Ltd pay dividends?
Venus Remedies Ltd has a dividend yield of 0.62%.
What is the Return on Equity (ROE) of Venus Remedies Ltd?
Venus Remedies Ltd reported a return on equity of 8.08%. Its debt-to-equity ratio is 0.02.
Company Information
Incorporated in 1989, Venus Remedies Ltd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies. It operates across 100+ countries, with a product basket of 195+, 1,100+ marketing authorisations and 700+ dossiers filed.{# {# https://www.bseindia.com/xml-data/corpfiling/AttachHis/29971821-bfab-4659-a9d8-7cf5dc170d02.pdf#page=36 #} #}
Website venusremedies.com
CEO Mr. Pawan Chaudhary
Employees 1,298
Listed 2006-12-20
Face Value ₹ 10
Issued Size 1,33,66,988
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VENUSREM.md for Venus Remedies Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.